Product Availability: In Stock (FedEx delivery within 2 business days).
Ordering: To place an order please use Add to Cart button (account not required).
Transfection Reagent for 293 Cells (Embryonic Kidney Cells, CRL-1573)
- Two component formulation enhances lipid mediated transfection efficiency
- Optimized easy-to-use transfection protocol provided for transfection of siRNA, DNA, mRNA, and microRNA
- Kit includes Transfection Enhancer, Complex Condenser reagent and recommended transfection protocol
- High transfection efficacy in the presence of serum
- Expand your RNAi application with a reagent optimized for delivery of both siRNA and plasmid
- Reproducible transfection results
- Works well for standard reverse transfection and high-throughput applications
- Download in vitro 293 transfection protocol: [PDF]
- Download 293 CRISPR/Cas9 transfection protocol: [PDF]
- Download PowerPoint presentation for 293 cells transfection kit: [PPT]
- UPC/GTIN/EAN: 860002089709
Brand: ALTOGEN®, developed and manufactured by Altogen Biosystems
Reagent exhibits at least 90% transfection efficiency of siRNA delivery. Transfection efficiency was determined by real-time RT-PCR.
Transfection Protocol and MSDS:
Download Altogen Biosystems 293 Transfection Protocol: [PDF]
Download MSDS: [PDF]
293 Cell Line:
The 293 cell line was established from embryonic and tumorigenic kidney cells of a human fetus. This cell line expresses vitronectin receptors composed of the integrin beta-1 subunit as well as the vitronectin receptor alpha-v subunit and could be useful for testing efficacy of virucide. This cell line also makes an excellent transfection host. The 293 cell line is a hypotriploid human cell line that exhibits epithelial morphology. The modal chromosome number of 64 occurs nearly in 30% of cells. 293 cells contain Adenovirus 5 DNA on the left end sequence of the viral genome. All other 293 types of cell lines are derivatives of this parent cell line. All of the daughter cells exhibit similar characteristics. The 293 cell line was derived from cancerous fetal kidney tissue and is a reliable host for transfection studies carried out for cancer research. Altogen Biosystems provides transfection kits with low cytotoxicity for the 293 cell line.
The 293 cell line is a human embryonic kidney cell line that was established in 1973 by transforming human embryonic kidney cells with adenovirus type 5 DNA. 293 cells are commonly used in molecular biology and biotechnology research, particularly in the production of recombinant proteins and viral vectors for gene therapy. They have been widely used as a host for the production of adenoviral vectors, retroviral vectors, lentiviral vectors, and other viral vectors that are used to introduce genetic material into cells. 293 cells have a high transfection efficiency, which means that they are able to take up and express foreign DNA at high levels. They are also known to have a relatively stable karyotype, which means that they maintain a consistent chromosome number and structure over many generations. 293 cells can be cultured as adherent monolayers or in suspension, and they are commonly used in large-scale bioreactors for the production of recombinant proteins and viral vectors. They are also used as a model system for studying various cellular processes, including protein trafficking, protein folding, and signal transduction. Additionally, 293 cells have been used to study the molecular mechanisms of various human diseases, including cancer and viral infections.
Figure 1. GAPD mRNA levels were quantified using real-time RT-PCR in the 293 cells transfected with siRNAs targeting GAPD or non-silencing siRNA. Forty-eight hours post-transfection, the cells were harvested and analyzed by real-time RT-PCR for GAPD mRNA expression levels. Data were normalized against the 18S rRNA signal. Control samples were either mock-transfected or untreated. Values are normalized to untreated sample. Data are means ± SD (n=5).
Figure 2. Protein expression of GAPD in 293 cells. DNA plasmid expressing GAPD or siRNA targeting GAPDH were transfected into 293 cells following Altogen Biosystems transfection protocol. At 72 hours post-transfection the cells were analyzed by Western Blot for protein expression levels (normalized by total protein, 10 µg of total protein loaded per each well). Untreated cells used as a negative control.
Selected in vivo transfection product citations (ALTOGEN® IN VIVO Transfection Kits used in the following publications):
- Nature. 2008 454(7203):523-7. Innate immunity induced by composition-dependent RIG-I …Saito et al [PDF]
- Am J Pathology. 2010 177(4):1870-80. Role of ocular complement factor H in a murine model … Lyzogubov et al [PDF]
- Nature Biotechnology. 2011 29(4):341-5. Delivery of siRNA to the mouse brain by … Alvarez-Erviti et al [PDF]
- Cancer Research. 2011 71(15):5144-53. Inhibition of miR-193a expression by… Iliopoulos et al [PDF]
- Hypertension. 2015 65(2):430-9. Neurokinin 3 receptor and phosphocholine transferase… Parchim et al [PDF]
Altogen Biosystems is a life sciences company that manufactures over 100 cell type specific and preoptimized transfection kits, elecroporation buffers, and targeted in vivo delivery kits and reagents. Advanced formulation of reagents and optimized transfection protocols provide highly efficient intracellular delivery of biomolecules (proteins, DNA, mRNA, shRNA and siRNA, and small molecule compounds). Read more about transfection technology at Altogen’s Transfection Resource.
Altogen Research Services:
Altogen Labs provides GLP compliant contract research studies for preclinical research, IND applications, and drug development. Biology CRO services include: Xenograft models (90+), development of stable cell lines, ELISA assay development, cell-based and tissue targeted RNAi studies, safety pharm/tox assays, and other studies (visit AltogenLabs.com).
- 0.5 ml (Catalog #1151)
- 1.5 ml (Catalog #1152)
- 1.5 ml CRISPR (Catalog #2204)
- 8.0 ml (Catalog #7014)